Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short Interest

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 25,783 shares, an increase of 92.0% from the October 15th total of 13,429 shares. Based on an average daily volume of 18,220 shares, the short-interest ratio is presently 1.4 days. Currently, 0.0% of the shares of the company are sold short.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP purchased a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group makes up 6.0% of MAC Alpha Capital Management LP’s investment portfolio, making the stock its 2nd biggest holding. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have issued reports on PHAR shares. HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research report on Tuesday, September 22nd. Weiss Ratings raised Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday. Canaccord Genuity Group increased their price target on Pharming Group from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Oppenheimer reiterated an “outperform” rating on shares of Pharming Group in a research note on Wednesday, October 28th. Finally, Zacks Research raised Pharming Group from a “strong sell” rating to a “hold” rating in a report on Friday, October 23rd. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Pharming Group currently has an average rating of “Moderate Buy” and a consensus price target of $39.67.

Read Our Latest Research Report on PHAR

Pharming Group Stock Performance

Shares of NASDAQ PHAR traded down $0.35 during midday trading on Friday, hitting $12.60. The company’s stock had a trading volume of 5,072 shares, compared to its average volume of 17,426. The stock has a fifty day moving average price of $10.96 and a 200 day moving average price of $13.48. Pharming Group has a one year low of $9.11 and a one year high of $21.34. The company has a current ratio of 3.23, a quick ratio of 2.65 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $891.83 million, a price-to-earnings ratio of 39.38 and a beta of -0.05.

Pharming Group (NASDAQ:PHAR – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.09. The company had revenue of $117.60 million for the quarter, compared to analysts’ expectations of $117.60 million. Pharming Group had a net margin of 6.23% and a return on equity of 8.70%. On average, research analysts forecast that Pharming Group will post 0.34 EPS for the current fiscal year.

About Pharming Group

(Get Free Report)

Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

Featured Stories

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.